Available online at ajdhs.com

Asian Journal of Dental and Health Sciences

Open Access to Dental and Medical Research

Copyright  © 2025 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

 

Nitric Oxide Bioavailability and Vascular Dysfunction in Sickle Cell Patients: A Pathophysiological Nexus

* Emmanuel Ifeanyi Obeagu 

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

 

 

Introduction

Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin, known as hemoglobin S (HbS). Under low oxygen conditions, HbS polymerizes, causing red blood cells (RBCs) to adopt a sickled shape, which results in vascular occlusion and hemolysis. These sickled cells contribute to chronic hemolytic anemia, recurrent vaso-occlusive episodes, and progressive organ damage. Vascular dysfunction is a hallmark feature of SCD, playing a central role in the development of both acute and chronic complications. Among the key molecular players in vascular homeostasis is nitric oxide (NO), a potent vasodilator and anti-inflammatory agent produced by endothelial cells. However, in SCD, the bioavailability of NO is significantly reduced, contributing to the pathogenesis of vascular complications and poor clinical outcomes ^1-2. NO is synthesized in endothelial cells by endothelial nitric oxide synthase (eNOS) using L-arginine as a substrate. Once produced, NO diffuses into smooth muscle cells, where it activates soluble guanylate cyclase (sGC), leading to the production of cyclic guanosine monophosphate (cGMP). This process induces vasodilation and maintains vascular tone. Furthermore, NO has anti-thrombotic and anti-inflammatory properties, preventing the adhesion of platelets and leukocytes to the endothelium. In healthy individuals, NO maintains vascular homeostasis by regulating blood flow, reducing blood clotting, and preventing endothelial dysfunction. However, in SCD, NO’s crucial role is impaired by multiple pathophysiological factors, leading to significant consequences for vascular health ^3-4.

One of the primary contributors to NO depletion in SCD is the chronic hemolysis of sickled red blood cells. The release of free hemoglobin from lysed RBCs into the bloodstream leads to an increase in cell-free hemoglobin levels, which can bind to and scavenge NO. This results in the rapid inactivation of NO, thereby reducing its bioavailability and function. Furthermore, the presence of free hemoglobin promotes oxidative stress, which further damages the endothelium and reduces the activity of eNOS, the enzyme responsible for NO production. As a result, the normal vasodilatory effect of NO is diminished, contributing to a state of endothelial dysfunction that predisposes individuals with SCD to vaso-occlusive crises and other cardiovascular complications ⁵. In addition to the scavenging effects of free hemoglobin, the activity of the enzyme arginase is significantly elevated in SCD. Arginase competes with endothelial nitric oxide synthase (eNOS) for the substrate L-arginine, a key precursor in the production of NO. Increased arginase activity reduces the availability of L-arginine for NO synthesis, further exacerbating the deficit of NO in the vascular system. This competition between arginase and eNOS for L-arginine is a critical factor in the pathophysiology of vascular dysfunction in SCD, highlighting the importance of understanding how this enzyme dysregulation contributes to the disease process ^6-7. The consequences of reduced NO bioavailability in SCD are far-reaching, extending beyond the immediate effects of vasoconstriction and platelet aggregation. Chronic NO depletion in SCD promotes endothelial activation, characterized by the upregulation of adhesion molecules such as VCAM-1 and ICAM-1. These molecules facilitate the adhesion of sickled erythrocytes and leukocytes to the vascular endothelium, leading to further obstruction of blood flow and exacerbating the process of vaso-occlusion. Moreover, the reduced anti-thrombotic effect of NO increases the risk of thrombus formation and deep vein thrombosis. Over time, these processes contribute to the development of long-term vascular complications, such as pulmonary hypertension, stroke, and organ damage, particularly in the lungs, kidneys, and brain ^8-9.

Nitric Oxide and Endothelial Homeostasis

Nitric oxide (NO) is a pivotal signaling molecule that plays a critical role in maintaining endothelial homeostasis, which is essential for vascular health. The endothelial cells lining the blood vessels are responsible for regulating vascular tone, blood flow, and immune cell trafficking. These cells continuously interact with circulating blood components, and NO are central to these interactions, ensuring that the blood vessels function properly and that the delicate balance between vasodilation and vasoconstriction is maintained ¹⁰. Endothelial cells synthesize NO through the action of endothelial nitric oxide synthase (eNOS), which converts L-arginine into NO in the presence of oxygen. NO diffuses from the endothelium into the smooth muscle cells of the blood vessel walls, where it activates soluble guanylate cyclase (sGC). This leads to the generation of cyclic guanosine monophosphate (cGMP), a secondary messenger that induces vasodilation by reducing intracellular calcium levels, thereby relaxing the smooth muscle cells. The relaxation of smooth muscle results in the widening of the blood vessels (vasodilation), which lowers vascular resistance and promotes blood flow. This process is vital for regulating blood pressure and ensuring that oxygen and nutrients are delivered efficiently to tissues throughout the body ^11-12.

In addition to its vasodilatory effects, NO has several other important functions in endothelial homeostasis. It acts as an anti-inflammatory agent by inhibiting the adhesion of leukocytes to the endothelial cells, which helps prevent excessive inflammation and tissue damage. Furthermore, NO exerts anti-thrombotic effects by inhibiting platelet aggregation and promoting fibrinolysis. This prevents the formation of clots that could obstruct blood vessels and disrupt blood flow. NO also plays a role in regulating vascular permeability, ensuring that the endothelial barrier remains intact to prevent unwanted leakage of plasma proteins into tissues ¹³. However, the bioavailability of NO can be compromised in various pathological conditions, including sickle cell disease (SCD). In SCD, a combination of factors such as increased oxidative stress, chronic hemolysis, and the release of free hemoglobin leads to a significant reduction in NO levels. Free hemoglobin, released from lysed red blood cells, scavenges NO, reducing its availability and impairing its vasodilatory effects. This contributes to endothelial dysfunction, characterized by a shift toward vasoconstriction, increased leukocyte adhesion, and a pro-thrombotic state. These changes underlie many of the vascular complications seen in SCD, including vaso-occlusive crises, pulmonary hypertension, and organ damage ^14-15. In addition to hemolysis, other factors contribute to NO depletion in SCD. Arginase, an enzyme that metabolizes L-arginine, the precursor for NO synthesis, is upregulated in SCD. This results in a competition for L-arginine between arginase and eNOS, further limiting the substrate available for NO production. As a result, endothelial cells in SCD patients are less capable of producing NO, exacerbating endothelial dysfunction and contributing to the vascular complications associated with the disease ¹⁶.

Mechanisms of Nitric Oxide Depletion in Sickle Cell Disease (SCD)

In sickle cell disease (SCD), the bioavailability of nitric oxide (NO) is significantly reduced, contributing to vascular dysfunction, inflammation, and other severe complications. Several interrelated mechanisms are responsible for the depletion of NO in SCD, including chronic hemolysis, oxidative stress, upregulation of arginase, and endothelial dysfunction. These mechanisms work synergistically, creating a vicious cycle that exacerbates the clinical manifestations of the disease.

1. Free Hemoglobin Scavenging of NO

One of the primary mechanisms of NO depletion in SCD is the release of free hemoglobin into the bloodstream due to the chronic hemolysis of sickled red blood cells. When red blood cells become deformed and brittle, they rupture prematurely, releasing hemoglobin into the plasma. This free hemoglobin binds directly to NO, forming a nitrosylated product, which effectively inactivates NO and reduces its bioavailability. The scavenging of NO by free hemoglobin is particularly problematic because it prevents NO from performing its normal vasodilatory function, leading to vasoconstriction, increased blood pressure, and reduced tissue oxygenation. This process is thought to contribute significantly to the vascular complications observed in SCD, such as pulmonary hypertension and stroke ¹⁷.

2. Oxidative Stress and Impaired Endothelial Nitric Oxide Synthase (eNOS) Activity

Oxidative stress plays a crucial role in the depletion of NO in SCD. The chronic hemolysis of sickled cells leads to the release of heme, which induces the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). These highly reactive molecules not only damage endothelial cells but also impair the function of endothelial nitric oxide synthase (eNOS), the enzyme responsible for the production of NO. ROS can induce the uncoupling of eNOS, which converts it from a NO-producing enzyme to a superoxide-generating enzyme. The production of superoxide (O2−) further exacerbates oxidative stress and competes with NO, reducing its availability. This impairment in eNOS function is a critical contributor to endothelial dysfunction and the inability of blood vessels to dilate properly in response to NO ¹⁸.

3. Upregulation of Arginase and Substrate Competition

Another key mechanism of NO depletion in SCD is the increased activity of arginase, an enzyme that metabolizes L-arginine, the substrate required for NO synthesis by eNOS. In SCD, arginase levels are elevated due to the stress and inflammation caused by hemolysis. Arginase hydrolyzes L-arginine into ornithine and urea, thereby reducing the amount of L-arginine available for eNOS to produce NO. This competition for L-arginine between eNOS and arginase is a critical factor in the depletion of NO. As arginase activity increases, the substrate for NO production becomes limited, exacerbating the deficit of NO in the circulation and contributing to the persistence of vascular dysfunction in SCD ¹⁹.

4. Hemolysis-Induced Inflammation and Immune Activation

The ongoing hemolysis in SCD also triggers a cascade of inflammatory responses that further contribute to NO depletion. The release of cell-free hemoglobin and other hemolytic products activates the innate immune system, leading to the production of pro-inflammatory cytokines and the recruitment of leukocytes to the site of injury. Inflammation increases the production of ROS and RNS, which not only damage endothelial cells but also reduce the bioavailability of NO. Additionally, pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) can downregulate eNOS expression, further impairing NO synthesis and exacerbating endothelial dysfunction ²⁰.

5. Impaired Nitric Oxide Synthase Coupling and eNOS Dysfunction

The activity of eNOS in SCD is further compromised by factors such as oxidative stress and altered redox status. Under normal conditions, eNOS functions as a dimer, efficiently converting L-arginine into NO. However, in the presence of excessive ROS and oxidative stress, eNOS can become uncoupled, meaning that instead of producing NO, it generates superoxide radicals. This uncoupling of eNOS not only contributes to a decrease in NO bioavailability but also increases the burden of oxidative stress, further damaging endothelial cells and exacerbating vascular dysfunction. This dysfunctional form of eNOS accelerates the pathological cycle of vascular injury in SCD ²¹.

6. Implications for Vascular Dysfunction and Clinical Outcomes

The depletion of NO in SCD has significant implications for vascular function and the progression of disease complications. The reduced NO bioavailability leads to endothelial dysfunction, characterized by impaired vasodilation, increased platelet aggregation, and enhanced leukocyte adhesion to the endothelium. These changes contribute to the formation of microvascular occlusions and increase the risk of thromboembolic events, which are common in SCD. Furthermore, impaired NO signaling is associated with the development of pulmonary hypertension, a leading cause of morbidity and mortality in SCD patients. By promoting vasoconstriction, oxidative stress, and thrombotic events, NO depletion exacerbates the severity of acute vaso-occlusive crises and contributes to long-term vascular complications, such as stroke, organ damage, and chronic kidney disease ²².

Vascular Consequences of Nitric Oxide Deficiency in Sickle Cell Disease (SCD)

Nitric oxide (NO) plays an essential role in maintaining vascular health by regulating blood vessel tone, inhibiting platelet aggregation, reducing inflammation, and preventing vascular smooth muscle cell proliferation. In sickle cell disease (SCD), a deficiency in NO bioavailability has profound consequences for vascular function, leading to a variety of complications that significantly impact patient outcomes. These vascular consequences are primarily driven by the loss of NO's vasodilatory effects, the promotion of vasoconstriction, and the dysregulation of endothelial function, which together contribute to the pathophysiology of SCD.

1. Endothelial Dysfunction

Endothelial cells are critical in regulating vascular tone and maintaining the integrity of the vascular wall. In SCD, the reduced bioavailability of NO leads to endothelial dysfunction, a state where the endothelium loses its ability to respond to stimuli that would normally induce vasodilation. The endothelial dysfunction in SCD is primarily a consequence of impaired NO signaling due to free hemoglobin scavenging NO, oxidative stress, and reduced eNOS activity. As a result, the endothelial cells become less capable of modulating blood vessel constriction and dilation, leading to a persistent state of vasoconstriction, which impairs blood flow. This diminished capacity to regulate vascular tone can result in various clinical manifestations, including chronic pain and ischemia ²³.

2. Increased Vascular Tone and Vasoconstriction

In a healthy vasculature, NO promotes vasodilation by activating soluble guanylate cyclase in smooth muscle cells, leading to the relaxation of vascular smooth muscle and subsequent vessel widening. In SCD, however, the depletion of NO causes a shift toward vasoconstriction, as the smooth muscle cells no longer receive the signal to relax. This increase in vascular tone can lead to increased blood pressure and reduced perfusion of tissues and organs. The reduced vasodilation also contributes to the pathogenesis of vaso-occlusive crises, which are a hallmark of SCD. During a vaso-occlusive crisis, blood vessels become obstructed due to the combination of increased viscosity, decreased nitric oxide levels, and abnormal red blood cell shapes, leading to ischemia and pain ²⁵.

3. Promotion of Thrombosis and Coagulation

NO has anti-thrombotic properties, as it inhibits platelet aggregation and prevents the formation of blood clots. In the absence of sufficient NO, there is a heightened risk of thrombosis in SCD patients. The reduced bioavailability of NO in SCD promotes platelet activation, increases endothelial cell adhesion molecules, and enhances the recruitment of leukocytes and platelets to the site of injury. These processes contribute to the formation of microthrombi within the blood vessels, which can exacerbate vaso-occlusion and lead to further ischemia. Additionally, the prothrombotic state increases the risk of stroke, myocardial infarction, and other thromboembolic events in individuals with SCD ²⁶.

4. Increased Leukocyte Adhesion and Inflammation

NO plays a critical role in modulating the inflammatory response within the vasculature by inhibiting the adhesion of leukocytes to the endothelial cells. In the absence of adequate NO levels, the inflammatory response is dysregulated, and there is increased adhesion of leukocytes to the endothelium. This exacerbates the inflammatory processes in SCD, promoting further endothelial injury and contributing to the development of chronic inflammation. The enhanced leukocyte adhesion also facilitates the progression of tissue damage and vascular occlusion, which underlie many of the acute and chronic complications seen in SCD patients, such as organ damage, stroke, and pulmonary hypertension ²⁷.

5. Pulmonary Hypertension

Pulmonary hypertension (PH) is a common and severe complication in SCD, characterized by elevated pressure in the pulmonary arteries. NO deficiency plays a central role in the pathogenesis of PH in SCD. In the pulmonary circulation, NO normally helps regulate vascular tone and maintain a low-pressure environment. However, in the setting of NO depletion, there is increased pulmonary vascular resistance, which leads to right heart strain and eventually right heart failure. The combination of chronic hemolysis, oxidative stress, and impaired eNOS function in SCD promotes vasoconstriction in the pulmonary vasculature, worsening pulmonary hypertension. PH is a significant contributor to morbidity and mortality in SCD patients, with a poor prognosis if left untreated ²⁸.

6. End-organ Damage

The vascular consequences of NO deficiency extend to various organs, where the impaired blood flow and increased vascular tone contribute to end-organ damage. Chronic kidney disease, stroke, and liver dysfunction are common complications in individuals with SCD, and the reduced NO bioavailability exacerbates these conditions. In the kidneys, the increased vascular tone and reduced perfusion can lead to glomerular injury and tubulointerstitial fibrosis, ultimately resulting in chronic kidney disease. Similarly, the combination of vaso-occlusion and endothelial dysfunction in the brain increases the risk of ischemic stroke in SCD patients. Organ damage in SCD is multifactorial but is aggravated by the diminished capacity of NO to protect against vascular injury and maintain normal blood flow ²⁹.

Therapeutic Strategies to Restore Nitric Oxide Bioavailability in Sickle Cell Disease (SCD)

Restoring nitric oxide (NO) bioavailability is an important therapeutic target in sickle cell disease (SCD), as the deficiency of NO contributes significantly to the vascular dysfunction, inflammation, and thrombotic complications characteristic of the disease. Various therapeutic strategies have been explored to enhance NO production, minimize its scavenging, and improve endothelial function in individuals with SCD. These strategies involve both pharmacological interventions and lifestyle modifications aimed at restoring endothelial homeostasis, reducing oxidative stress, and improving vascular function.

1. L-Arginine Supplementation

L-arginine is the amino acid substrate required for the production of NO by endothelial nitric oxide synthase (eNOS). In SCD, the bioavailability of L-arginine is often reduced due to the increased activity of arginase, which hydrolyzes L-arginine into ornithine. Supplementing with L-arginine has been investigated as a strategy to restore NO production by providing an additional substrate for eNOS. Clinical studies have shown that L-arginine supplementation can improve endothelial function, reduce pulmonary artery pressure, and enhance vasodilation in SCD patients. While the results are promising, the effect of L-arginine supplementation may be variable, and its use should be considered alongside other therapies aimed at reducing oxidative stress and inflammation ³⁰.

2. Nitrate Therapy

Nitrate therapy is another strategy to restore NO bioavailability in SCD. Nitrates are metabolized to release NO or NO-like species, which can help restore vasodilation and reduce vascular tone. Organic nitrates, such as nitroglycerin, and inorganic nitrates, such as sodium nitrite, have been explored in preclinical and clinical studies for their ability to increase NO levels in the circulation. In SCD, nitrate therapy may improve endothelial function, reduce pulmonary hypertension, and alleviate symptoms of vaso-occlusive crises by enhancing blood flow and reducing ischemia. However, the long-term use of nitrates in SCD requires caution due to the potential for tolerance development and adverse effects on blood pressure regulation ³¹.

3. Antioxidant Therapies

Since oxidative stress is a key contributor to NO depletion in SCD, antioxidants that neutralize reactive oxygen species (ROS) and prevent endothelial cell damage have been investigated as therapeutic options. Vitamin E, a potent antioxidant, has been shown to reduce oxidative stress in SCD and may help improve NO bioavailability. Other antioxidant compounds, such as N-acetylcysteine (NAC) and polyphenols (found in fruits, vegetables, and tea), have demonstrated potential in reducing ROS and improving endothelial function. These antioxidants may indirectly enhance NO signaling by decreasing the oxidative damage to eNOS and other endothelial cell components. The use of antioxidants as adjunctive therapies may be effective in managing vascular dysfunction and improving overall patient health in SCD ³².

4. Hydroxyurea Therapy

Hydroxyurea, a standard therapeutic agent in SCD, has demonstrated multiple benefits beyond its effects on hemoglobin F (HbF) induction. One of its potential benefits is its ability to increase NO production. Hydroxyurea has been shown to stimulate eNOS activity and enhance NO bioavailability in patients with SCD. This effect is thought to be mediated by the reduction of hemolysis and the associated release of free hemoglobin, which scavenges NO. Additionally, hydroxyurea can decrease oxidative stress, thereby protecting endothelial cells and promoting vascular health. The combination of these effects may help mitigate the vascular complications of SCD, including pulmonary hypertension and stroke. Hydroxyurea remains one of the cornerstones of SCD treatment due to its ability to reduce the frequency of vaso-occlusive crises and improve overall patient outcomes ³³.

5. Gene Therapy and Cellular Approaches

Emerging gene therapy and cellular approaches offer promising potential for restoring NO bioavailability in SCD. Recent advances in gene editing technologies, such as CRISPR-Cas9, have made it possible to correct the underlying genetic mutation in hemoglobin (HbS) or to induce the expression of fetal hemoglobin (HbF), which reduces the sickling of red blood cells and alleviates hemolysis. By reducing hemolysis and increasing HbF levels, gene therapy may reduce the amount of free hemoglobin available to scavenge NO. Additionally, stem cell-based therapies, including the use of autologous stem cells genetically modified to express HbF, may improve blood flow and endothelial function by reducing hemolysis and inflammation. While these approaches are still in experimental stages, they hold great promise for long-term management of SCD and its associated vascular complications ³⁴.

6. Phosphodiesterase Type 5 (PDE5) Inhibitors

PDE5 inhibitors, such as sildenafil, are known to enhance NO signaling by inhibiting the breakdown of cyclic guanosine monophosphate (cGMP), which is produced in response to NO activation of guanylate cyclase. By preserving cGMP levels, PDE5 inhibitors can enhance the vasodilatory effects of NO and improve endothelial function. In SCD, PDE5 inhibitors have been explored as potential therapies for pulmonary hypertension and other forms of vascular dysfunction. Clinical studies have shown that sildenafil and other PDE5 inhibitors can improve exercise capacity, reduce pulmonary artery pressure, and alleviate symptoms of pulmonary hypertension in SCD patients. While these drugs are generally well tolerated, careful monitoring is necessary due to potential side effects and interactions with other medications used in SCD management ^35-36.

7. Lifestyle Modifications

In addition to pharmacological interventions, lifestyle modifications can play a key role in restoring NO bioavailability in SCD. Regular physical activity has been shown to increase endothelial NO production and improves vascular health. Exercise stimulates eNOS activity, increases blood flow, and helps maintain optimal vascular tone. Moreover, maintaining a healthy diet rich in antioxidants (such as fruits, vegetables, and whole grains) and omega-3 fatty acids can help reduce oxidative stress and promote NO production. Avoiding smoking and managing other cardiovascular risk factors, such as hypertension, can also improve NO bioavailability and reduce the risk of vascular complications in SCD ³⁷.

Conclusion

Restoring nitric oxide (NO) bioavailability in sickle cell disease (SCD) represents a critical therapeutic strategy to address the vascular dysfunction and associated complications that significantly impact patient quality of life and longevity. The depletion of NO in SCD is a central mechanism underlying endothelial dysfunction, increased vascular tone, thrombosis, and inflammation. These pathophysiological processes contribute to many of the hallmark complications of the disease, including vaso-occlusive crises, pulmonary hypertension, stroke, and organ damage. Therapeutic interventions aimed at enhancing NO bioavailability, such as L-arginine supplementation, nitrate therapy, antioxidant treatment, hydroxyurea, and PDE5 inhibitors, show promise in improving vascular health in SCD patients. Additionally, emerging gene therapies and stem cell-based approaches offer the potential for long-term improvements by targeting the root causes of NO depletion, such as hemolysis and oxidative stress. While these therapies are promising, they require careful clinical evaluation to ensure efficacy and safety in diverse patient populations.

Conflict of Interest: Author declares no potential conflict of interest with respect to the contents, authorship, and/or publication of this article.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable. 

Data Availability Statement: The data supporting in this paper are available in the cited references. 

Ethics approval: Not applicable.

References

1. Gupta A. Sickle Cell Anemia and Related Hemoglobinopathies. InDecision Making Through Problem Based Learning in Hematology: A Step-by-Step Approach in patients with Anemia 2024: 269-289. Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-8933-1_21

2. Hassan MS, Nasrin T, Mahalka A, Hoque M, Ali S. A perspective on the genesis, diagnostics, and management of sickle cell disease. Egyptian Journal of Medical Human Genetics. 2024; 25(1):150. https://doi.org/10.1186/s43042-024-00623-1

3. Rajput HS, Kumari M, Talele C, Sajan C, Saggu V, Hadia R. Comprehensive Overview Of Sickle Cell Disease: Global Impact, Management Strategies, And Future Directions. Journal of Advanced Zoology. 2024; 45(1). https://doi.org/10.53555/jaz.v45i1.3390

4. Obeagu EI. Role of Autophagy in Modulating Oxidative Stress in Sickle Cell Disease: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):38-46. https://doi.org/10.23880/hij-16000247

5. Obeagu EI. Redox Regulation of Hemoglobin in Sickle Cell Disease: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):13-9.

6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. Int Res Med Health Sci. 2023 Sep 11;6:12-7.

7. Xiao R, Li L, Zhang Y, Fang L, Li R, Song D, Liang T, Su X. Reducing carbon and nitrogen loss by shortening the composting duration based on seed germination index (SCD@ GI): feasibilities and challenges. Science of The Total Environment. 2024:172883. https://doi.org/10.1016/j.scitotenv.2024.172883 PMid:38697528

8. Lin W, Lv X, Wang Q, Li L, Zou G. Nitrogen concentration dependent optical defects transition in single crystal diamond through low pressure high temperature annealing. Vacuum. 2025:114329. https://doi.org/10.1016/j.vacuum.2025.114329

9. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical & Experimental Pharmacology & Physiology. 2007 Sep 1;34(9). https://doi.org/10.1111/j.1440-1681.2007.04639.x PMid:17645642

10. Dijkmans T, Djokic MR, Van Geem KM, Marin GB. Comprehensive compositional analysis of sulfur and nitrogen containing compounds in shale oil using GC× GC-FID/SCD/NCD/TOF-MS. Fuel. 2015; 140:398-406. https://doi.org/10.1016/j.fuel.2014.09.055

11. Muehle M, Asmussen J, Becker MF, Schuelke T. Extending microwave plasma assisted CVD SCD growth to pressures of 400 Torr. Diamond and Related Materials. 2017; 79:150-163. https://doi.org/10.1016/j.diamond.2017.09.013

12. Obeagu EI, Obeagu GU. Immunization strategies for individuals with sickle cell anemia: A narrative review. Medicine. 2024; 103(38):e39756. https://doi.org/10.1097/MD.0000000000039756 PMid:39312357 PMCid:PMC11419550

13. Obeagu EI. Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. Annals of Medicine and Surgery.:10-97.

14. Obeagu EI. Erythropoeitin in sickle cell anaemia: a review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8. https://doi.org/10.22259/ijrsmhs.0502004

15. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: prevalence, impact, and interventions: a review. Medicine. 2024 May 17;103(20):e38164. https://doi.org/10.1097/MD.0000000000038164 PMid:38758879 PMCid:PMC11098235

16. Quemada M, Delgado A, Mateos L, Villalobos FJ. Nitrogen fertilization I: The nitrogen balance. InPrinciples of agronomy for sustainable agriculture 2024: 377-401. Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-69150-8_26

17. Krug EC, Winstanley D. The need for comprehensive and consistent treatment of the nitrogen cycle in nitrogen cycling and mass balance studies: I. Terrestrial nitrogen cycle. Science of the total environment. 2002; 293(1-3):1-29. https://doi.org/10.1016/S0048-9697(01)01133-0 PMid:12109464

18. Zhang CC, Zhou CZ, Burnap RL, Peng L. Carbon/nitrogen metabolic balance: lessons from cyanobacteria. Trends in plant science. 2018; 23(12):1116-1130. https://doi.org/10.1016/j.tplants.2018.09.008 PMid:30292707

19. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. The American journal of the medical sciences. 1990; 300(6):366-371. https://doi.org/10.1097/00000441-199012000-00005 PMid:2264574

20. Borel MJ, Buchowski MS, Turner EA, Peeler BB, Goldstein RE, Flakoll PJ. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. American Journal of Physiology-Endocrinology and Metabolism. 1998; 274(2):E357-364. https://doi.org/10.1152/ajpendo.1998.274.2.E357 PMid:9486169

21. Jackson AA. The use of stable isotopes to study nitrogen metabolism in homozygous sickle cell disease. InGenetic factors in nutrition. 1984: 297-315. Academic Press, New York. https://doi.org/10.1016/B978-0-12-715950-8.50024-X PMCid:PMC7131065

22. Schnog JJ, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, Muskiet FA. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Annals of Hematology. 2004; 83:371-375. https://doi.org/10.1007/s00277-004-0856-9 PMid:15054669

23. Darghouth D, Koehl B, Madalinski G, Heilier JF, Bovee P, Xu Y, Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. Blood, The Journal of the American Society of Hematology. 2011; 117(6):e57-66. https://doi.org/10.1182/blood-2010-07-299636 PMid:21135259

24. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Jama. 2005; 294(1):81-90. https://doi.org/10.1001/jama.294.1.81 PMid:15998894 PMCid:PMC2065861

25. Zhou Y, Yu X, Nicely A, Cunningham G, Challa C, McKinley K, Nickel R, Campbell A, Darbari D, Summar M, Majumdar S. Amino acid signature during sickle cell pain crisis shows significant alterations related to nitric oxide and energy metabolism. Molecular genetics and metabolism. 2022; 137(1-2):146-152. https://doi.org/10.1016/j.ymgme.2022.08.004 PMid:36030599

26. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. Haematologica. 2023; 108(12):3418. https://doi.org/10.3324/haematol.2023.283288 PMid:37439373 PMCid:PMC10690926

27. Obeagu EI, Prajapati SK, Maurya SD, Maternal Anemia in the Context of Infectious Diseases during Pregnancy: A Review, International Journal of Medical Sciences and Pharma Research, 2025;11(1):8-13 https://doi.org/10.22270/ijmspr.v11i1.134

28. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. Current Research in Biological Sciences. 2025;1(1):01-8.

29. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: diarrhea in sickle cell anemia. Medicine. 2024; 103(18):e38075. https://doi.org/10.1097/MD.0000000000038075 PMid:38701274 PMCid:PMC11062666

30. Obeagu EI, Obeagu GU. Living with sickle cell in Uganda: A comprehensive perspective on challenges, coping strategies, and health interventions. Medicine. 2024 Dec 20;103(51):e41062. https://doi.org/10.1097/MD.0000000000041062 PMid:39705436 PMCid:PMC11666137

31. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. Annals of Medicine and Surgery. 2024; 86(10):6021-6036. https://doi.org/10.1097/MS9.0000000000002534 PMid:39359845 PMCid:PMC11444627

32. Bell V, Varzakas T, Psaltopoulou T, Fernandes T. Sickle cell disease update: new treatments and challenging nutritional interventions. Nutrients. 2024; 16(2):258. https://doi.org/10.3390/nu16020258 PMid:38257151 PMCid:PMC10820494

33. Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease---A special nutritional consideration. Nutrition & metabolism. 2016; 13:1-2. https://doi.org/10.1186/s12986-016-0109-7 PMid:27508000 PMCid:PMC4977632

34. Patel S, Patel R, Mukkala SR, Akabari A. Emerging therapies and management approaches in sickle cell disease (SCD): A critical review. Journal of Phytonanotechnology and Pharmaceutical Sciences. 2023; 3(3):1-1. https://doi.org/10.54085/jpps.2023.3.3.3

35. Obeagu EI, Prajapati SK, Maurya SD, Anemia in Pregnancy: Exploring Non-Iron Deficiency Causes, International Journal of Medical Sciences and Pharma Research, 2025;11(1):1-7 https://doi.org/10.22270/ijmspr.v11i1.130

36. Boma PM, Kaponda AA, Panda J, Bonnechère B. Enhancing the management of pediatric sickle cell disease by integrating functional evaluation to mitigate the burden of vaso-occlusive crises. Journal of Vascular Diseases. 2024; 3(1):77-87. https://doi.org/10.3390/jvd3010007

37. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. Current Research in Biological Sciences. 2025;1(1):01-8.